Biomarin Pharmaceuticals (BMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Sales | 1,860,455 | 1,704,048 | 1,491,212 | 1,313,646 | 1,116,854 |
| Cost of Goods | 524,272 | 359,466 | 315,264 | 241,786 | 209,620 |
| Gross Profit | 1,336,183 | 1,344,582 | 1,175,948 | 1,071,860 | 907,234 |
| Operating Expenses | 1,379,895 | 1,445,505 | 1,299,736 | 1,087,346 | 1,711,283 |
| Operating Income | -43,440 | -100,457 | -123,524 | -14,700 | -803,429 |
| Interest Expense | 29,309 | 23,460 | 43,664 | 42,707 | 39,499 |
| Other Income | 23,752 | 29,106 | 24,483 | 21,532 | 11,878 |
| Pre-tax Income | -48,997 | -94,811 | -142,705 | -35,875 | -831,050 |
| Income Tax | -903,026 | -70,963 | -65,494 | 81,167 | -200,840 |
| Net Income Continuous | 854,029 | -23,848 | -77,211 | -117,042 | -630,210 |
| Net Income | $854,029 | $-23,848 | $-77,211 | $-117,042 | $-630,210 |
| EPS Basic Total Ops | 4.72 | -0.13 | -0.44 | -0.67 | -3.80 |
| EPS Basic Continuous Ops | 4.72 | -0.13 | -0.44 | -0.67 | -3.80 |
| EPS Diluted Total Ops | 4.50 | -0.13 | -0.44 | -0.67 | -3.81 |
| EPS Diluted Continuous Ops | 4.46 | -0.13 | -0.44 | -0.67 | -3.79 |
| EPS Diluted Before Non-Recurring Items | 0.68 | N/A | N/A | N/A | N/A |
| EBITDA(a) | $62,299 | $2,843 | $-27,495 | $76,238 | $-705,217 |